Episode 164 - Natalia Misciattelli - CEO of AAVantgarde

On this episode we discuss the AAVantgarde story with CEO, Natalia Misciatelli. Founded by Professor Alberto Auricchio in 2021 as a spin-out from Telethon Institute of Genetics and Medicine in Naples, we discuss their dual-vector and intein-based platforms and how the team are positioning to deliver large therapeutic genes for inherited retinal diseases. Backed by household VC names including; Forbion, Atlas Venture, & Sofinnova, Natalia and the team are pursuing game-changing prospects for Stargardt & Usher1b patients.Check this episode out to hear more about their programs, particularly ahead of ARVO where the team will share data from their LUCE ph1/2 study in Usher1b.